This page shows the latest SCLC news and features for those working in and with pharma, biotech and healthcare.
Tecentriq was the first approved cancer immunotherapy for the first-line treatment of adults with extensive-stage small cell lung cancer (SCLC) in combination with chemotherapy.
Imfinzi is already used to treat unresectable, stage 3 non-small cell lung cancer (NSCLC) and extensive-stage small cell lung cancer (ES-SCLC) as well as advanced bladder cancer. ... The company has a broad development programme for Imfinzi plus
AstraZeneca has announced that its PD-L1 inhibitor Imfinzi (durvalumab) showed a ‘sustained and clinically meaningful’ survival benefit for patients with extensive stage cell lung cancer (ES-SCLC). ... For treatment purpose, clinicians divide SCLC
More Imfinzi data will be presented at the European Society for Medical Oncology (ESMO) Congress, showing three-year overall survival data in extensive-stage small cell lung cancer (ES-SCLC), the
Tecentriq is currently approved for the front-line treatment of small cell lung cancer (SCLC), a market where the checkpoint inhibitor has been able to carve a niche away from the ... SCLC is less common than NSCLC but tends to be more aggressive,
Keytruda has become a new standard-of-care for the treatment of newly-diagnosed NSCLC, although this immunotherapy failed to demonstrate the same benefit in SCLC. ... SCLC is less common than NSCLC but tends to be more aggressive, growing more quickly
More from news
Approximately 6 fully matching, plus 41 partially matching documents found.
triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer.
Rova-T showed a 44% overall response rate in DLL-expressing small cell lung cancer (SCLC) patients who had failed one or more standard therapies.
July finalised a $730m exclusive deal with Boehringer Ingelheim for HM61713, an orally active third generation EGFR agent in small cell lung cancer (SCLC).
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...